Date of birth: unknown.The patient¿s age was used.Investigation summary: it was reported in the process of intravenous injection with gamma globulin, the patient suffered sudden consciousness loss and cardiac arrest.As a sample was unavailable for return, a thorough sample investigation could not be completed.A device history and sterilization record review was completed for provided material number 306594, lot number 1057946.The review did not reveal any detected quality issues during the production of this lot that could have contributed to the reported result.There was no documentation of any defect during the entire production run of this batch.The sterilization records were reviewed confirming that sterilization was compliant to requirements.To date, there have been no other similar events reported for this lot.A review of the applicable end user risk assessments indicate that the potential risk of the reported event was assessed appropriately in the risk management documentation.Based on the investigation and with no sample analysis the symptom reported by the customer could not be confirmed and a probable root cause could not be offered.Complaints received for this device and reported condition will continue to be tracked and trended.Our quality team regularly reviews the collected data for identification of emerging trends.
|
It was reported that the bd posiflush¿ syringe was used in conjunction with intravenous gamma globulin injection, but the patient suffered a sudden loss of consciousness, went into cardiac arrest, and passed away after rescue attempts.No further information was provided by the customer.The following information was provided by the initial reporter, translated from (b)(6) to english: "in the process of intravenous injection with gamma globulin, the patient suffered suddenly consciousness loss and cardiac arrest, and patient was dead after rescue".
|